Nasdaq

Plus Therapeutics, Inc. Secures $1.6 Million Advance Payment from CPRIT to Support CNS Cancer Research and Development

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, announced it has received a $1.6 million advance ...
Yahoo Finance

5N Plus Inc. to Further Increase Space Solar Cell Production Capacity

AI, connectivity, observation and security needs fueling strong demand for solar cell technology MONTREAL, Feb. 2, 2026 /CNW/ - 5N Plus Inc. (TSX: VNP) ("5N+" or the "Company"), a leading global ...
Nasdaq

Plus Therapeutics, Inc. to Host Business Update Conference Call on June 26, 2025

Plus Therapeutics, Inc. announced that it will provide a business update on June 26, 2025, before the market opens. The management team will host a conference call and webcast at 9:00 a.m. ET to ...

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

The MSA includes the technology transfer of the REYOBIQ manufacturing process, Rhenium-186 isotope processing, analytical methods, as well as technical and regulatory expertise supporting future ...
Newswire

5N Plus Inc. Reports Fourth Quarter and Fiscal Year 2025 Financial Results

MONTRÉAL, Feb. 24, 2026 /CNW/ - 5N Plus Inc. (TSX: VNP) ("5N+" or "the Company"), a leading global producer of specialty semiconductors and performance materials, today announced its financial results ...